FX007
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by Bender the Bot (talk | contribs) at 03:40, 7 March 2017 (→top: HTTP→HTTPS, per BRFA 8 using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
FX007 is a selective small-molecule TrkA antagonist that is under development by Flexion Therapeutics for the local treatment of postoperative pain.[1] It is currently in the preclinical stage of development.[2] The drug was licensed by Flexion from AstraZeneca.[3] FX007 has also attracted interest as a potential treatment of osteoarthritis.[1]
See also
References
- ^ Kavanaugh, Taylor E.; Werfel, Thomas A.; Cho, Hongsik; Hasty, Karen A.; Duvall, Craig L. (2015). "Particle-based technologies for osteoarthritis detection and therapy". Drug Delivery and Translational Research. doi:10.1007/s13346-015-0234-2. ISSN 2190-393X.
External links
| Angiopoietin |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTF |
| ||||||||||
| EGF (ErbB) |
| ||||||||||
| FGF |
| ||||||||||
| HGF (c-Met) |
| ||||||||||
| IGF |
| ||||||||||
| LNGF (p75NTR) |
| ||||||||||
| PDGF |
| ||||||||||
| RET (GFL) |
| ||||||||||
| SCF (c-Kit) |
| ||||||||||
| TGFβ |
| ||||||||||
| Trk |
| ||||||||||
| VEGF |
| ||||||||||
| Others |
| ||||||||||
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=FX007&oldid=769024328"